within Pharmacolibrary.Drugs.D_Dermatologicals.D01A_AntifungalsForTopicalUse.D01AC13_Omoconazole;
model Omoconazole 
   extends Pharmacolibrary.Drugs.ATC.D.D01AC13;

  annotation(Documentation(
    info ="<html><body><p>Omoconazole is an imidazole derivative antifungal agent used primarily for topical treatment of superficial mycoses, particularly dermatophyte and yeast infections of the skin. It is classified under the ATC code D01AC13. Omoconazole is not widely used and is not currently approved or marketed in many countries.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic studies exist for omoconazole in humans. No clinical data are available regarding its absorption, distribution, metabolism, or excretion following topical or other routes of administration.</p><h4>References</h4><ol><li><p>Hashiguchi, T, et al., &amp; Yamaguchi, H (1997). Study of the effective dose of a topical antifungal agent, omoconazole nitrate, on the basis of percutaneous pharmacokinetics in guinea-pigs and mice. <i>The Journal of pharmacy and pharmacology</i> 49(8) 757–761. DOI:<a href=&quot;https://doi.org/10.1111/j.2042-7158.1997.tb06107.x&quot;>10.1111/j.2042-7158.1997.tb06107.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9379351/&quot;>https://pubmed.ncbi.nlm.nih.gov/9379351</a></p></li><li><p>Gip, L (1988). The in vitro determination of lingering antimycotic effect of two 1% omoconazole-nitrate cream formulations following single topical application. <i>Mycoses</i> 31(3) 155–158. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3393168/&quot;>https://pubmed.ncbi.nlm.nih.gov/3393168</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Omoconazole;
